多奈哌齐治疗阿尔茨海默病的疗效相关基因多态性研究进展

Progress in Related Single Nucleotide Polymorphism in the Therapeutic Response of Donepezil in Patients with Alzheimer′s Disease

目的综述多奈哌齐治疗轻中度阿尔茨海默病(AD)的疗效相关基因多态性的研究进展,为其疗效相关研究及临床合理使用提供参考。方法检索Pub Med及CNKI等数据库中关于影响多奈哌齐治疗AD相关疗效的影响因素,分析与多奈哌齐疗效相关的基因多态性特征。结果与结论多奈哌齐临床治疗个体差异大的主要原因可能与遗传因素密切相关。其中CYP2D6,CY3A4,APOE,ESR1,BCHE,PON-1,CHRNA7及CHAT的基因多态性与多奈哌齐疗效有关,未来可能成为多奈哌齐治疗轻中度AD的遗传标记物。

Objective To summarize the progress in related single nucleotide polymorphism in the clinical efficacy of donepezil in pa-tients with Alzheimer′s disease, to provide evidence to related study and clinical applications of donepezil. Methods Using databases such as Pub Med and CNKI to analyze the genetic influencing factor and the clinical efficacy of donepezil for treating Alzheimer′s dis-ease. Results and Conclusion The rate of clinical efficacy of patients to donepezil varies, most likely because of their genetic background. The polymorphism of CYP2D6, CY3A4, APOE, ESR1, BCHE, PON- 1, CHRNA7 and CHAT were closely related to the therapeutic response of donepezil in patient with Alzheimer′s disease. They can be taken in consider to become the future biomarker in clinical therapy of donepezil.